TRGV2: A Potential Cancer Treatment Target (G6974)

Target Name: TRGV2

NCBI ID: G6974

TRGV2

Other Name(s): TCRGV2 | T cell receptor gamma variable 2 | VIS2

TRGV2: A Potential Cancer Treatment Target

TRGV2 (Tumor-associated gene V2) is a gene that has been identified as a potential drug target for cancer treatment. It is a member of the gene family known as the T-cell receptor gene family, which is involved in the development and regulation of T cells, a type of white blood cell that plays a critical role in the immune system.

TRGV2 is located on chromosome 6 and encodes a protein known as TCRGV2. This protein is a key component of the T-cell receptor, which is a protein that is responsible for recognizing and responding to foreign substances in the body, such as viruses and bacteria. TRGV2 is thought to be involved in the regulation of T-cell receptor function, and it is possible that it may be a useful target for cancer treatment.

One of the reasons why TRGV2 is considered a potential drug target is that it is expressed in a variety of tissues and cells, including tissues that are commonly affected by cancer. For example, TRGV2 is expressed in the skin, the liver, and the lungs, which are all tissues that are commonly affected by skin cancer, lung cancer, and other types of cancer. This makes it a potential target for cancer treatments that can be applied directly to these affected tissues.

Another reason why TRGV2 is considered a potential drug target is that it is involved in the development and regulation of T cells, which are a critical part of the immune system. T cells are responsible for identifying and destroying foreign substances in the body, and they are an important part of the immune system's ability to protect the body against disease. TRGV2 is thought to be involved in the regulation of T-cell receptor function, which may be important for the immune system's ability to detect and respond to cancer cells.

In addition to its potential role in the immune system, TRGV2 is also thought to be involved in the regulation of cell signaling pathways that are important for the development and growth of cancer cells. For example, TRGV2 has been shown to be involved in the regulation of theNotch signaling pathway, which is a pathway that is important for the development and growth of cancer cells.

Despite these potential benefits, it is important to note that TRGV2 is not yet a proven drug target for cancer treatment. Further research is needed to determine exactly how TRGV2 functions in the immune system and how it might be able to be used to treat cancer. If TRGV2 is indeed a useful drug target, it may be possible to develop cancer treatments that target this protein and use it to treat disease.

Protein Name: T Cell Receptor Gamma Variable 2

Functions: V region of the variable domain of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:23348415, PubMed:28920588). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRGV2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRGV2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets